Swiss Biotech – Industry news, events, directory, Swiss Biotech Association

Get the insight

Swiss Biotech Report 2026

How did we fare in 2025?

Our association in facts and figures

In print & digitally

The leading compedium of Swiss Biotech

Become a Member

Loads of reasons to join

Invest in Swiss biotechs

Discover investment and partnering opportunities

Talent meets opportunities

Become part of the thriving community

Create lasting business ties

Connect with the Swiss biotech ecosystem

Total revenues reached a record CHF 7.5 billion in 2025 (CHF 7.2 billion in 2024) with more companies maturing to the commercial stage and a continuously growing demand for specialized CDMO services. Funding increased by 2.1% to CHF 2.6 billion. In a notable shift, investments in privately funded companies achieved a record CHF 1.15 billion – an increase of 38% compared to 2024, and a record 45%
May 5, 2026

We are tracking an ongoing and escalating fraud campaign targeting Swiss Biotech Association members and Swiss Biotech Day participants. Multiple fraudulent domains and Gmail accounts have already been identified and reported to their registrars and hosts; several have been taken down, but new ones continue to appear. Please read this alert carefully and share it within your organization.
April 16, 2026

Strategic acquisition strengthens InSphero’s presence in the United States and expands advanced imaging and phenotypic analysis capabilities for drug discovery and safety testing
May 21, 2026

Mabylon AG, a leader in human-derived, half-life extended multi-specific antibodies, today reported positive Phase IA clinical trial data demonstrating a favorable safety profile of its lead candidate MY006. Safety Monitoring Committee (SMC) recommended initiation of Part B of the peanut allergy trial in patients. Funding secured for follow-on tree pollen program MY010. The multi-specific antibody
May 19, 2026

Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Timeline for submission of NDA of deucrictibant IR for the on-demand treatment of HAE attacks remains on-track in 1H2026 Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks Cash and cash equival
May 12, 2026